Why the study?
Does measurement of B-type natriuretic peptide improve the diagnosis and management of patients with congestive heart failure?
Does measurement of B-type natriuretic peptide improve the diagnosis and management of patients with congestive heart failure?
Answers are grounded in this paper and cite their sources.
BNP is a useful bedside test for diagnosing heart failure in patients with acute dyspnea and for guiding heart failure therapy.
Until recently no simple specific test existed for the differentiation of decompensated heart failure from other causes of acute dyspnoea, or to assess the prognosis of patients with severe heart failure or to optimize heart failure therapy in an individual patient. Measurement of B-type natriuretic peptide has become available as an easy-to-per-form bedside test. Several studies have demonstrated it's usefulness in the emergency room to differentiate heart failure from other causes of acute dyspnoea or to guide the complex drug therapy in an individual patient with heart failure. This article gives a short overview on the clinical experience to use BNP-blood levels for the diagnosis and treatment guidance of heart failure.
No takes yet. Share an insight, caveat, or question.
Mueller et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: